Compositions and methods regarding engineered and non-engineered γ δ T-cells for treatment of hematological tumors

A δ1 γδ T cell comprising:

• a. a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises
• (i) a binding domain that specifically binds to CD20;
• (ii) a CD8α hinge domain;
• (iii) a CD8 α transmembrane domain;
• (iv) a costimulatory signaling region;
• and
• (v) a CD3α signaling domain;
• or
• b. a polypeptide comprising a CAR comprising an amino acid sequence encoded by the nucleic acid of (a);
• wherein the δ1 γδ T cell functionally expresses the binding domain of the polypeptide or the nucleic acid encoded CAR on the surface of the δ1 γδ T cell, and wherein
• the binding domain comprises anti-CD20 antibody 3H7;
• or
• the binding domain comprises the complementary determining regions of anti-CD20 antibody 3H7.